1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
- 2010
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
- 2007
-
Mark
EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.
(
- Contribution to journal › Article
-
Mark
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray"
(
- Contribution to journal › Scientific review
-
Mark
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
(
- Contribution to journal › Article
- 2006
-
Mark
Clinical applications of newer radionuclide therapies
(
- Contribution to journal › Article
- 2003
-
Mark
Tumour therapy with radionuclides: assessment of progress and problems
(
- Contribution to journal › Scientific review